Joint Formulary & PAD

Ethinylestradiol with levonorgestrel - Contraception

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important
Preferred

Preferred brands = Levest, Rigevidon, Maexeni,

 

Status 2

Green
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

Microgynon 30 ED, TriRegol, Logynon, Logynon ED

 

Status 3

Green (see narrative)
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

Ovranette / Ambelina / Microgynon 30 - not for new initiations. Existing patients may remain on current brand.

 

Status 4

Non Formulary
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

Elevin brand is not a cost effective option. 

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Ethinylestradiol with levonorgestrel
Indication :
Contraception
Group Name :
Keywords :
combined hormonal contraceptive, CHC
Brand Names Include :
Levest, Rigevidon, Maexeni, Ovranette, Ambelina, Microgynon 30, Elevin
Important Information :

NOTE - Trusts are unlikely to initiate oral contraceptives but will obtain supplies for the continuation of treatment during in-patient episodes.

Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
4

Other Indications

Below are listed other indications that Ethinylestradiol with levonorgestrel is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Contraception.

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee agreed the traffic light status of this drug and indication as part of the Joint Formulary review.